IntroductionFollowing the INPULSIS and ASCEND studies, leading to the first two approved antifibrotic therapies for patients with IPF, ongoing investigations are firmly exploring novel agents for a targeted effective and better tolerated therapy able to improve the natural history of the disease.Areas coveredThis review aims to analyze recent advances in pharmacological research of IPF, discussing the currently available treatments and the novel drugs under investigation in phase 3 trials, with particular emphasis on BI 1015550 and inhaled treprostinil. The literature search utilized Medline and Clinicaltrials.org databases. Critical aspects of clinical trial design in IPF are discussed in light of recently completed phase III studies.Expert opinionWhile randomized clinical trials in IPF are currently underway, future objectives should explore potential synergistic benefits when combining novel molecules with the existing therapies and identify more specific molecular targets. Moreover, refining the study design represent another crucial goal. The aim of the pharmacological research will be not only stabilizing but also potentially reversing the fibrotic changes in IPF.

Sofia, C., Comes, A., Sgalla, G., Richeldi, L., Promising advances in treatments for the management of idiopathic pulmonary fibrosis, <<EXPERT OPINION ON PHARMACOTHERAPY>>, 2024; 25 (6): 717-725. [doi:10.1080/14656566.2024.2354460] [https://hdl.handle.net/10807/282560]

Promising advances in treatments for the management of idiopathic pulmonary fibrosis

Sofia, Carmelo;Comes, Alessia;Sgalla, Giacomo;Richeldi, Luca
Ultimo
2024

Abstract

IntroductionFollowing the INPULSIS and ASCEND studies, leading to the first two approved antifibrotic therapies for patients with IPF, ongoing investigations are firmly exploring novel agents for a targeted effective and better tolerated therapy able to improve the natural history of the disease.Areas coveredThis review aims to analyze recent advances in pharmacological research of IPF, discussing the currently available treatments and the novel drugs under investigation in phase 3 trials, with particular emphasis on BI 1015550 and inhaled treprostinil. The literature search utilized Medline and Clinicaltrials.org databases. Critical aspects of clinical trial design in IPF are discussed in light of recently completed phase III studies.Expert opinionWhile randomized clinical trials in IPF are currently underway, future objectives should explore potential synergistic benefits when combining novel molecules with the existing therapies and identify more specific molecular targets. Moreover, refining the study design represent another crucial goal. The aim of the pharmacological research will be not only stabilizing but also potentially reversing the fibrotic changes in IPF.
2024
Inglese
Sofia, C., Comes, A., Sgalla, G., Richeldi, L., Promising advances in treatments for the management of idiopathic pulmonary fibrosis, <<EXPERT OPINION ON PHARMACOTHERAPY>>, 2024; 25 (6): 717-725. [doi:10.1080/14656566.2024.2354460] [https://hdl.handle.net/10807/282560]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/282560
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact